Showing 7591-7600 of 8238 results for "".
- AAD Releases New App to Aid Patients with Chronic Hiveshttps://practicaldermatology.com/news/aad-releases-new-app-to-aid-patients-with-chronic-hives/2458798/The American Academy of Dermatology (AAD) released its Chronic Hives Patient App, which offers tools and resources for chronic hives management. The free mobile app, developed with a grant from Novartis Pharmaceuticals Corp., can help patients learn more about their condition, find a doctor, trac
- Almirall Acquires Veltin® and Altabax® from Stiefel, a GSK Companyhttps://practicaldermatology.com/news/almirall-acquires-veltin-and-altabax-from-stiefel-a-gsk-company/2458802/Almirall has acquired the rights to Veltin® and Altabax, from Stiefel, a GSK company, in exchange for distribution rights to Toctino® and an undisclosed cash payment.
- Pfizer and Allergan to Combinehttps://practicaldermatology.com/news/pfizer-and-allergan-to-combine/2458803/The boards of directors for Pfizer Inc. and Allergan plc have both unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer will combine with Allergan in a stock transaction currently valued at $363.63 per Allergan share, for a total enterprise v
- Novartis receives FDA regular approval for Tafinlar + Mekinist for Melanomahttps://practicaldermatology.com/news/novartis-receives-fda-regular-approval-for-tafinlar-mekinist-for-melanoma/2458804/The FDA granted regular approval for the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) from Novartis for the treatment of patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma as detected by an FDA-approved test. This is th
- Ortek Therapeutics Files Patent Applications for New Microbiome to Reduce S. Aureus Proliferationhttps://practicaldermatology.com/news/ortek-therapeutics-files-patent-applications-for-new-microbiome-to-reduce-s-aureus-proliferation/2458808/Stony Brook University and Ortek Therapeutics, Inc. filed two patent applications in the United States and internationally for nutrient based compositions utilizing innovative microbiome technology. Developed at Stony Brook University, these compositions have been exclusively licensed to Ortek as
- ASDSA Patient Safety Hero Honorees Recognizedhttps://practicaldermatology.com/news/asdsa-patient-safety-hero-honorees-recognized/2458810/The American Society for Dermatologic Surgery Association (ASDS) announced its Patient Safety Hero Award recipients during the recent 2015 ASDS Annual Meeting in Chicago to recognize leaders who have taken an active role in the promotion and protection of patient safety in dermatologic procedures
- American Skin Association Medical Advisory Committee Names New Co-Chairhttps://practicaldermatology.com/news/american-skin-association-medical-advisory-committee-names-new-co-chair/2458807/American Skin Association (ASA) named current member Robert Modlin, MD as Co-Chair of its Medical Advisory Committee (MAC) alongside Dr. David Norris. Dr. Modlin is Chief of the Division of Dermatology and Professor of Dermatology in the Department of Medicine and Department of Microbiology, Immu
- ASDS Awards 10 Clinical Research Grantshttps://practicaldermatology.com/news/asds-awards-10-clinical-research-grants/2458811/The American Society for Dermatologic Surgery (ASDS) has awarded a total of $96,000 to 10 new clinical research projects through its Cutting Edge Research Grant program. This year’s research projects will focus on topics ranging from examining the effectiveness of specific lasers on surgica
- Immune Pharmaceuticals: FDA Accepts IND Application for Bertilimumab for Bullous Pemphigoidhttps://practicaldermatology.com/news/immune-pharmaceuticals-fda-accepts-ind-application-for-bertilimumab-for-bullous-pemphigoid/2458813/Immune Pharmaceuticals, Inc. has indicated that the FDA has accepted the Company's Investigational New Drug (IND) application for its first in class, lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP). This FDA acceptance enables the Company to expand recruitme
- Cosmetic Bootcamp University Exceeds Goalshttps://practicaldermatology.com/news/cosmetic-bootcamp-university-a-success/2458815/Now completing its session in Philadelphia, the Cosmetic Bootcamp University session has exceeded goals, organizers report. Cosmetic Bootcamp seeks to improve patient outcomes in a manner not possible at other meetings by focusing on core specialists in dermatology, plastic surgery, op